The European Commission (EC) has approved Incyte’s Minjuvi (tafasitamab) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) who have received a minimum of one systemic therapy line.
Alnylam Pharmaceuticals is set to invest $250m in the expansion of its facility in Norton, Massachusetts, US, to meet the growing global demand for RNA interference (RNAi) therapeutics.
Zealand Pharma and OTR Therapeutics have signed a strategic collaboration and licence agreement aimed at jointly discovering and developing therapies for several targets in metabolic diseases.
Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m.
Made Scientific and Cellergy Therapeutics have formed a manufacturing partnership to advance the latter’s CLG-001 mitochondrial therapy toward first-in-human studies.
Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they supplied adulterated attention-deficit hyperactivity disorder (ADHD) medication to children in the US state.
Norway-based biotechnology company Calluna Pharma has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead clinical candidate, CAL101.
Johnson & Johnson (J&J) has secured approval from the US Food and Drug Administration (FDA) for a subcutaneous (SC) induction regimen of Tremfya (guselkumab) in adults with moderately to severely active ulcerative colitis (UC).
Biogen has signed a definitive agreement to acquire Alcyone Therapeutics for advancing the development and commercialisation of ThecaFlex DRx drug delivery system.
The European Commission (EC) has sanctioned the use of Deciphera Pharmaceuticals’ Romvimza (vimseltinib) to treat tenosynovial giant cell tumour (TGCT) in adults.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.